ReviewJournal of clinical and experimental hepatology2011
Pathogenesis, diagnosis, and treatment of hepatic encephalopathy.
Review in Journal of clinical and experimental hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01722578 (Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Meta-analysis of probiotics efficacy in the treatment of minimum hepatic encephalopathy.Liver international : official journal of the International Association for the Study of the Liver · 2024Pooled it
- L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.The Cochrane database of systematic reviews · 2018Pooled it
- Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.Alimentary pharmacology & therapeutics · 2026Trial
- Revealing the protective potential of D-(-)-Quinic acid against thioacetamide-induced hepatic encephalopathy in rats.Scientific reports · 2025Article
- Brain magnetic resonance imaging findings in hyperammonemic hepatic encephalopathy: A case series and literature review.Biomedical reports · 2025Article
- Assessment of microstructural abnormalities in gray and white matter of minimal hepatic encephalopathy patients using diffusion kurtosis imaging and their associations with neurocognitive dysfunction.Frontiers in human neuroscience · 2025Article
- Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.Journal of clinical medicine · 2022Article
- Acute Acquired Metabolic Encephalopathy Based on Diffusion MRI.Korean journal of radiology · 2021Review
- Therapeutic plasma exchange in liver failure.World journal of hepatology · 2021Review
- Role of extracellular vesicles in liver diseases and their therapeutic potential.Advanced drug delivery reviews · 2021Review
- Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy.Internal medicine (Tokyo, Japan) · 2021Article
- Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives.Frontiers in cell and developmental biology · 2021Review
- Thalamic Structural Connectivity Abnormalities in Minimal Hepatic Encephalopathy.Frontiers in neuroanatomy · 2021Article
- Reduced Cortical Complexity in Cirrhotic Patients with Minimal Hepatic Encephalopathy.Neural plasticity · 2020Article
- Multimodal MR imaging in hepatic encephalopathy: state of the art.Metabolic brain disease · 2018Review
- Endogenous Expression of ODN-Related Peptides in Astrocytes Contributes to Cell Protection Against Oxidative Stress: Astrocyte-Neuron Crosstalk Relevance for Neuronal Survival.Molecular neurobiology · 2018Article
- Identification of modules of hepatic encephalopathy based on protein-protein network and gene expression data.Experimental and therapeutic medicine · 2018Article
- The Cerebellum of Patients with Steatohepatitis Shows Lymphocyte Infiltration, Microglial Activation and Loss of Purkinje and Granular Neurons.Scientific reports · 2018Article
- Arachidonic Acid Metabolism Pathway Is Not Only Dominant in Metabolic Modulation but Associated With Phenotypic Variation After Acute Hypoxia Exposure.Frontiers in physiology · 2018Article
- Carnosine Reduces Oxidative Stress and Reverses Attenuation of Righting and Postural Reflexes in Rats with Thioacetamide-Induced Liver Failure.Neurochemical research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a neuropsychiatric disorder seen in patients with advanced liver disease or porto-systemic shunts. Based on etiology and severity of HE, the World Congress of Gastroenterology has divided HE into categories and sub-categories. Many user-friendly computer-based neuropsychiatric tests are being validated for diagnosing covert HE. Currently, emphasis is being given to view HE deficits as a continuous spectrum rather than distinct stages. Ammonia is believed to play crucial role in pathogenesis of HE via astrocyte swelling and cerebral edema. However, evidence has been building up which supports the synergistic role of oxidative stress, inflammation and neurosteroids in pathogenesis of HE. At present, treatment of HE aims at decreasing the production and intestinal absorption of ammonia. But as the role of new pathogenetic mechanisms becomes clear, many potential new treatment strategies may become available for clinician.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.